Aim immunotech announces publication of new analysis of the mechanism of action of ampligen as a potential prophylactic therapy against ebola virus disease

Ocala, fla., march 08, 2023 (globe newswire) -- aim immunotech inc. (nyse american: aim) (“aim” or the “company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases — including covid-19, the disease caused by the sars-cov-2 virus — today announced the publication of a new analysis of the ability of aim's drug ampligen (rintatolimod) to inhibit the spread and replication of ebola virus disease, which adds to the body of evidence supporting ampligen's potential as an early-onset prophylactic therapy against human ebola outbreaks.
AIM Ratings Summary
AIM Quant Ranking